TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28448087

Group type: EXPERIMENTAL
Intervention: Mediterranean type diet (DIET) for 16 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: Normal diet (CON)
Number of subjects: 99
Study: 25581251

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1320
Study: 23179176

Group type: EXPERIMENTAL
Intervention: THC/CBD spray (2 sprays: 5.4 mg THC and 5.0 mg CBD, 4 sprays: 10.8 mg THC and 10.0 mg CBD, 8 sprays: 21.6 mg THC and 20.0 mg CBD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: THC/CBD spray (multiple doses: 2, 4, or 8 sprays once daily for nine consecutive days)
Number of subjects: 0
Study: 21526980

Group type: EXPERIMENTAL
Intervention: Tablets containing 400 mg of colostrum protein taken thrice daily with bicarbonate buffer
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tablets containing 400 mg colostrum protein given with buffer
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tablets containing 400 mg colostrum protein given without buffer
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tablets containing 200 mg colostrum protein given without buffer
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 18834057

Group type: EXPERIMENTAL
Intervention: Problem-based learning as a teaching strategy
Number of subjects: 0
Study: 16492716

Group type: EXPERIMENTAL
Intervention: 2 Hz electrical stimuli
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.1 Hz electrical stimuli
Number of subjects: 8
Study: 14632250

Group type: EXPERIMENTAL
Intervention: OPCABG (off-pump CABG)
Number of subjects: 43

Group type: COMPARATOR
Intervention: CPB CABG (CABG with cardiopulmonary bypass)
Number of subjects: 43
Study: 11702833

Group type: EXPERIMENTAL
Intervention: Cervical vacuum cap cannula
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metal cannula
Number of subjects: 50
Study: 9692538

Group type: EXPERIMENTAL
Intervention: Infertile women (n=47)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Fertile controls (n=47)
Number of subjects: 47
Study: 7834164

Group type: COMPARATOR
Intervention: Controlled release dosage form of sodium monofluoro phosphate (NaMFP) at a dose of 160 mg, with a drug to polymer ratio of 1:1.1, delivered over 6 hours.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate release dosage form of sodium monofluoro phosphate (NaMFP) used as a control in a two‐period crossover study.
Number of subjects: 0
Study: 2968885

Group type: EXPERIMENTAL
Intervention: Bedtime ultralente administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Morning ultralente administration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both regimens (bedtime and morning)
Number of subjects: 10
Study: 31149709

Group type: EXPERIMENTAL
Intervention: l-leucine supplementation (7.5 g·d‐1) with resistance training (3 times/week)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (l-alanine) with resistance training (3 times/week)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (l-leucine and l-alanine)
Number of subjects: 19
Study: 27571766

Group type: EXPERIMENTAL
Intervention: Assessment of Visual Awareness (AVA) test in PTV
Number of subjects: 70

Group type: COMPARATOR
Intervention: Assessment of Visual Awareness (AVA) test in STV
Number of subjects: 70
Study: 25563714

Group type: EXPERIMENTAL
Intervention: Methotrexate (10 mg orally once a week for 3 months)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (treatment as usual)
Number of subjects: 72
Study: 22801943

Group type: EXPERIMENTAL
Intervention: Twice daily exercise until discharge home and twice weekly as outpatient for 8 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control arm received protocolized inpatient respiratory physiotherapy
Number of subjects: 15
Study: 20199815

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of recombinant human erythropoietin (rhEPO, 50 U/kg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group without IV treatment before PCI
Number of subjects: 57
Study: 19246447

Group type: EXPERIMENTAL
Intervention: 21‐mg nicotine patch for 6 months
Number of subjects: 20
Study: 17105759

Group type: EXPERIMENTAL
Intervention: PCI and stenting with optimal medical therapy
Number of subjects: 2166

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 2166
Study: 15589713

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 0
Study: 11759140

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (high bupivacaine)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine (high ropivacaine)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine (low bupivacaine)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine (low ropivacaine)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 0.1% study drug infusion with 0.6 microgram/mL of sufentanil
Number of subjects: 68
Study: 9359507

Group type: EXPERIMENTAL
Intervention: Early intensification at 5 weeks
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Late intensification at 20 weeks
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Both early and late intensification
Number of subjects: 618

Group type: COMPARATOR
Intervention: Neither early nor late intensification
Number of subjects: 618
Study: 8259774

Group type: EXPERIMENTAL
Intervention: Engerix-B 20 micrograms
Number of subjects: 460

Group type: COMPARATOR
Intervention: Recombivax HB 10 micrograms
Number of subjects: 460
Study: 2939871

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 42
Study: 27817096

Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 552

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 552
Study: 27719705

Group type: EXPERIMENTAL
Intervention: Free gingival graft
Number of subjects: 30

Group type: COMPARATOR
Intervention: Apically repositioned flap
Number of subjects: 30
Study: 24667461

Group type: EXPERIMENTAL
Intervention: GLP-1 and insulin during normoglycemic-hyperinsulinemic clamp
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: GLP-1 during normoglycemic-normoinsulinemic clamp
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: GLP-1 and insulin during normoglycemia
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Hyperglycemic-hyperinsulinemic clamp with GLP-1
Number of subjects: 2

Group type: COMPARATOR
Intervention: Hyperglycemic-normoinsulinemic clamp
Number of subjects: 2
Study: 22148879

Group type: EXPERIMENTAL
Intervention: Incredible Years BASIC parent training program (IYBP)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 149
Study: 20124563

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 752

Group type: COMPARATOR
Intervention: Etanercept 50 mg once weekly
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 752
Study: 17823565

Group type: EXPERIMENTAL
Intervention: NIPSV (pressure support level, 12 cmH2O; positive end-expiratory pressure, 5 cmH2O; FiO2, 0.6)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard treatment (oxygen 8 l/min via Venturi face mask)
Number of subjects: 23
Study: 16207770

Group type: EXPERIMENTAL
Intervention: Motivational processes influencing risk assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commitment to the present partner
Number of subjects: 0
Study: 11915588

Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol 2 mg plus norethisterone acetate 1 mg (E2 + NETA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Raloxifene HCl 60 mg
Number of subjects: 28
Study: 9895083

Group type: EXPERIMENTAL
Intervention: Diclofenac (IV bolus of 0.7 mg/kg followed by a constant infusion of 0.15 mg x kg(‐1) x h(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (equal volume administered)
Number of subjects: 20
Study: 10481503

Group type: EXPERIMENTAL
Intervention: Low-power laser therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 32
Study: 1830287

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine/Mefruside combination
Number of subjects: 0
Study: 6661343

Group type: EXPERIMENTAL
Intervention: Timolol treatment for 2 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carbimazole treatment after timolol
Number of subjects: 18
Study: 31502232

Group type: EXPERIMENTAL
Intervention: Adolescent childbearing (first birth) among those with low levels of grade attainment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adolescent childbearing (first birth) among those with higher levels of grade attainment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adolescent childbearing (first birth)
Number of subjects: 0
Study: 29205909

Group type: EXPERIMENTAL
Intervention: HAPA-treatment (sedentary behavior)
Number of subjects: 52

Group type: COMPARATOR
Intervention: HAPA-control (nutrition)
Number of subjects: 52
Study: 28848898

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrrolate (IND/GLY) 27.5/15.6 or 27.5/31.2 µg twice daily (b.i.d.)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Indacaterol (IND) 75 µg once daily (o.d.)
Number of subjects: 85
Study: 24281848

Group type: EXPERIMENTAL
Intervention: Parental stress measured using the Parenting Stress Index, short form.
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Parental stress measured prior to depression diagnosis.
Number of subjects: 106
Study: 22093775

Group type: EXPERIMENTAL
Intervention: Abarelix initiation therapy for 12 weeks followed by LHRH agonist (leuprolide or goserelin) for 8 weeks
Number of subjects: 176

Group type: COMPARATOR
Intervention: LHRH agonist therapy (leuprolide or goserelin)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Abarelix initiation therapy
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Abarelix initiation therapy and LHRH agonist maintenance therapy
Number of subjects: 176
Study: 20361916

Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agomelatine 50 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18771988

Group type: EXPERIMENTAL
Intervention: Transversal expansion
Number of subjects: 811

Group type: COMPARATOR
Intervention: Cephalad-caudad expansion
Number of subjects: 811
Study: 16183466

Group type: EXPERIMENTAL
Intervention: Motivational interviewing-based intervention
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 228
Study: 12202435

Group type: EXPERIMENTAL
Intervention: Rescue ICSI of unfertilized oocytes (group I; n = 120)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (ICSI cycles; group II; n = 280)
Number of subjects: 400
Study: 10404423

Group type: EXPERIMENTAL
Intervention: Hoasca (2 ml/kg body weight)
Number of subjects: 15
Study: 8944861

Group type: EXPERIMENTAL
Intervention: Personal health education intervention with three visits per year from a health visitor.
Number of subjects: 688

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 688
Study: 1924661

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intermenstrual phase
Number of subjects: 33

Group type: COMPARATOR
Intervention: Luteal phase
Number of subjects: 33

Group type: COMPARATOR
Intervention: Menstrual phase
Number of subjects: 33
Study: 6805495

Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31296081

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10942

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10942

Group type: EXPERIMENTAL
Intervention: CEC identified MIs
Number of subjects: 10942

Group type: EXPERIMENTAL
Intervention: SI reported MIs
Number of subjects: 10942

Group type: EXPERIMENTAL
Intervention: CEC and SI reported MIs
Number of subjects: 10942

Group type: EXPERIMENTAL
Intervention: CEC but not SI reported MIs
Number of subjects: 10942

Group type: EXPERIMENTAL
Intervention: SI but not CEC reported MIs
Number of subjects: 10942
Study: 27879959

Group type: EXPERIMENTAL
Intervention: Balance Training (BT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 40
Study: 26372211

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 23232754

Group type: EXPERIMENTAL
Intervention: 5% dextrose‐0.9% saline
Number of subjects: 202

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 202
Study: 21158934

Group type: EXPERIMENTAL
Intervention: UV-B exposure of 3.0 SED for 4 sessions
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: UV-B exposure of 0.375 SED for 4 sessions
Number of subjects: 55
Study: 19843565

Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy for 6 weeks, tailored to individual performance, supervised by a physical therapist, with home exercises for 3 months
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual care (wait and see approach, rest during pain, refrain from pain provoking activities)
Number of subjects: 131
Study: 17561562

Group type: EXPERIMENTAL
Intervention: Topical betamethasone 0.1%
Number of subjects: 51

Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 51

Group type: COMPARATOR
Intervention: None (Control)
Number of subjects: 51
Study: 15382775

Group type: EXPERIMENTAL
Intervention: Ball-retained overdentures
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bar-retained overdentures
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Magnet-retained overdentures
Number of subjects: 36
Study: 12154263

Group type: EXPERIMENTAL
Intervention: Social problem‐solving telephone partnership intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study: 9661231

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 98

Group type: COMPARATOR
Intervention: Supportive housing
Number of subjects: 98
Study: 7916925

Group type: EXPERIMENTAL
Intervention: 5 mg OKT3
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 10 mg OKT3
Number of subjects: 29

Group type: COMPARATOR
Intervention: 5 mg OKT3 (initial three doses)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 10 mg OKT3 (initial three doses)
Number of subjects: 29
Study: 1369882

Group type: EXPERIMENTAL
Intervention: Surgically treated cases with wire loop (cerclage)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conservatively managed patients
Number of subjects: 39

Group type: COMPARATOR
Intervention: Patients operated after Weber
Number of subjects: 39
Study: 6778673

Group type: EXPERIMENTAL
Intervention: Elementary diet (water, electrolytes, carbohydrates, fat short-chain peptides via a jejunal tube)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional treatment (water, electrolytes, and carbohydrates by intravenous route)
Number of subjects: 20
Study: 31355654

Group type: EXPERIMENTAL
Intervention: Mindfulness induction
Number of subjects: 0
Study: 28087807

Group type: EXPERIMENTAL
Intervention: Prehospital LAMS
Number of subjects: 1632

Group type: EXPERIMENTAL
Intervention: EPA LAMS
Number of subjects: 1632

Group type: EXPERIMENTAL
Intervention: EPA National Institutes of Health Stroke Scale
Number of subjects: 1632

Group type: COMPARATOR
Intervention: Prehospital LAMS vs EPA National Institutes of Health Stroke Scale
Number of subjects: 1632

Group type: COMPARATOR
Intervention: Prehospital LAMS vs Prehospital Glasgow Coma Scale
Number of subjects: 1632
Study: 26474943

Group type: EXPERIMENTAL
Intervention: Telmisartan 20 mg
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 336

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Telmisartan treated arms
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Telmisartan treated dose arms
Number of subjects: 336
Study: 23803236

Group type: COMPARATOR
Intervention: C‐MVR group (complete preservation of anterior and posterior mitral leaflets and subvalvular apparatus)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: P‐MVR group (anterior leaflet and subvalvular apparatus excised, posterior leaflet and subvalvular apparatus preserved)
Number of subjects: 128
Study: 22306586

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 kD) 180 µg/week and ribavirin 800 mg/day
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 kD) and ribavirin
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: threshold exposures to both drugs
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: ribavirin 1000 or 1200 mg/day
Number of subjects: 287
Study: 19765449

Group type: EXPERIMENTAL
Intervention: Losartan for 1 year
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study: 17531532

Group type: EXPERIMENTAL
Intervention: Pergolide (47 patients)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (53 patients)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Unmedicated patients (Group 1)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Unmedicated patients (Group 2)
Number of subjects: 200
Study: 14984856

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 51
Study: 11463136

Group type: EXPERIMENTAL
Intervention: Perospirone 8 to 48 mg/day
Number of subjects: 304

Group type: COMPARATOR
Intervention: Haloperidol 2 to 12 mg/day
Number of subjects: 304

Group type: COMPARATOR
Intervention: Mosapramine 50 to 300 mg/day
Number of subjects: 304
Study: 10095686

Group type: EXPERIMENTAL
Intervention: Alternative cleansing regimens (not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soap and water
Number of subjects: 0
Study: 2596678

Group type: EXPERIMENTAL
Intervention: Interpleural bupivacaine, 20 ml of a 0.5% solution with adrenaline 5 micrograms/ml
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intramuscular pethidine, 1 mg/kg
Number of subjects: 24
Study: 337989

Group type: EXPERIMENTAL
Intervention: Halothane in oxygen in a closed circuit
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Halothane and 66% nitrous oxide in oxygen in a Magill circuit
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Artificial ventilation with 66% nitrous oxide in oxygen (IPPV group)
Number of subjects: 90
Study: 31776849

Group type: EXPERIMENTAL
Intervention: Health coach, text message, and Fitbit intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Fitbit-only control
Number of subjects: 59
Study: 31300528

Group type: EXPERIMENTAL
Intervention: Parent-only treatment with booster sessions (n = 44)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Parent-only treatment without booster sessions (n = 43)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard treatment (ST) (n = 87)
Number of subjects: 174
Study: 28821686

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 25761977

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/day
Number of subjects: 720

Group type: COMPARATOR
Intervention: Glimepiride ≤6 mg/day
Number of subjects: 720
Study: 23647373

Group type: EXPERIMENTAL
Intervention: Tefinostat (CHR‐2845) at doses of 20‐640 mg, administered orally once daily.
Number of subjects: 18
Study: 21072688

Group type: EXPERIMENTAL
Intervention: Bipolar energy sealing system (B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ultrasonic coagulation (UC)
Number of subjects: 90
Study: 19026256

Group type: EXPERIMENTAL
Intervention: High-calorie meal (1000 kcal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium-calorie meal (500 kcal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-calorie meals (250 kcal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat content of the meal
Number of subjects: 0
Study: 17106267

Group type: EXPERIMENTAL
Intervention: rDEN2/4Delta30(ME) vaccine at a dose of 1,000 PFU
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rDEN2/4Delta30(ME) vaccine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15019365

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4 mg of triamcinolone acetonide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (non-injected eye)
Number of subjects: 15
Study: 11745819

Group type: EXPERIMENTAL
Intervention: SIRT + HAC
Number of subjects: 37

Group type: COMPARATOR
Intervention: HAC only
Number of subjects: 37
Study: 9280873

Group type: EXPERIMENTAL
Intervention: Cisplatin in combination with prolonged oral etoposide (100 mg/d for 14 days)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Prolonged oral etoposide therapy (100 mg/d for 14 or 21 days)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Cisplatin in combination with prolonged oral etoposide
Number of subjects: 79
Study: 8516090

Group type: EXPERIMENTAL
Intervention: Phototherapy alone
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Phototherapy plus oral agar
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Oral agar alone
Number of subjects: 208

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 208
Study: 3102414

Group type: EXPERIMENTAL
Intervention: Fast neutron therapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: 4MV photon therapy
Number of subjects: 168
Study: 29429057

Group type: EXPERIMENTAL
Intervention: Stainless steel K-files (SSK)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Self-Adjusting File (SAF)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ProTaper NEXT (PTN)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RECIPROC (REC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SAF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SSK
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PTN
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: REC
Number of subjects: 24
Study: 26980264

Group type: EXPERIMENTAL
Intervention: Topical diltiazem (3 times a day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34